# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k071692   
B. Purpose for Submission: New device   
C. Measurand: IgA and IgG Anti-tissue Transglutaminase (tTG) antibodies IgA and IgG Anti-Gliadin antibodies   
D. Type of Test: Semi-quantitative   
E. Applicant: TheraTest Laboratories, Inc.   
F. Proprietary and Established Names: TheraTest EL-tTG™ IgA/IgG TheraTest EL-Glia™ IgA/IgG

# G. Regulatory Information:

Regulation section: 21 $\ S$ CFR 866.5660 Multiple autoantibodies immunological test system 21 $\ S$ CFR 866.5750 Radioallergosorbent (RAST) immunological test system

2. Classification: Class II

3. Product codes: MVM, Autoantibodies, Endomysial (Tissue Transglutaminase) MST, Antibodies, Gliadin

4. Panel: Immunology (82)

# H. Intended Use:

1. Intended use(s): The TheraTest EL-tTG™ IgA/IgG and TheraTest EL-GLIA™ IgA/IgG Kits are enzyme-linked immunosorbent assay (ELISA) test systems for the semiquantitative measurement of IgA and IgG anti-tissue transglutaminase (tTG) and anti-gliadin antibodies in human serum. Detection and semi-quantitation of these antibodies is intended to aid the diagnosis of patients with gluten sensitive enteropathies: celiac disease and dermatitis herpetiformis, in conjunction with other clinical findings and laboratory tests.   
2. Indication(s) for use: Same as Intended use.   
3. Special conditions for use statement(s): For prescription only.   
4. Special instrument requirements: Microplate reader: Spectrophotometer with single $( 4 5 0 \mathrm { n m } )$ or dual ( $4 5 0 \mathrm { n m }$ , 620- $6 9 0 \mathrm { n m }$ reference) wavelength and ELISA plate washer (optional)

I. Device Description: Each device contains the following: microwell plate with breakaway microwell coated with either recombinant tTG or purified gliadin antigen; plate frame; assay controls (IgA or IgG positive and IgA or IgG negative); calibrators (IgA or IgG); tTG/ Gliadin goat anti-human IgA conjugate; tTG/ Gliadin goat anti-human IgG conjugate; TMB chromogen; wash buffer (10X) and stop solution.

J. Substantial Equivalence Information:

1. Predicate device name(s): ImmuLisa™ Anti-human Tissue Transglutaminase IgA ImmuLisa™ Anti-human Tissue Transglutaminase IgG ImmuLisa™ Anti-Gliadin Antibody IgA ImmuLisa™ Anti-Gliadin Antibody IgG

2. Predicate K number(s): k992878 (Anti-hu tTG IgA) k040095 (Anti-hu tTG IgG) k964341 (Anti-Gliadin IgA) k964344 (Anti-Gliadin IgG)

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=4>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>New Device</td><td rowspan=1 colspan=2>Predicate Device</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>TheraTest EL-tTGTMIgA/IgG andTheraTest EL-GLIATM IgA/IgG</td><td rowspan=1 colspan=1>ImmuLisaTAnti-hu tTGAntibodyIgA/IgG</td><td rowspan=1 colspan=1>ImmuLisaTAnti-GliadinAntibody IgGor IgA</td></tr><tr><td rowspan=1 colspan=1>Antigen</td><td rowspan=1 colspan=1>Human recombinanttTG and purifiedgliadin</td><td rowspan=1 colspan=1>Recombinanthuman tTG</td><td rowspan=1 colspan=1>Purifiedgliadin</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Platform</td><td rowspan=1 colspan=1>96 well microtiterplates coated withspecific antigen</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measurement</td><td rowspan=1 colspan=1>Semi-quantitative</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample volumerequired</td><td rowspan=1 colspan=1>10 μL</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Microplate Reader</td><td rowspan=1 colspan=1>Spectrophotometer</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Detection Method</td><td rowspan=1 colspan=1>Colorimetric</td><td rowspan=1 colspan=1>Same</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="4" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="2" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">TheraTest EL-tTGTM IgA/IgG andTheraTest EL-GLIATM IgA/IgG</td><td colspan="1" rowspan="1">ImmuLisaT Anti-human TissueTransglutaminaseIgA/IgG</td><td colspan="1" rowspan="1">ImmuLisaT Anti-Gliadin Antibody(IgG or IgA)</td></tr><tr><td colspan="1" rowspan="1">Intended use</td><td colspan="1" rowspan="1">For the semi-quantitativedetection of</td><td colspan="1" rowspan="1">For the semi-quantitativedetection of</td><td colspan="1" rowspan="1">For the semi-quantitativedetection of IgA</td></tr><tr><td>Item</td><td>Device IgA/IgG antibodies</td><td>Predicate IgA/IgG</td><td>or IgG antibodies</td></tr><tr><td></td><td>to human recombinant tTG and purified gliadin</td><td>antibodies to recombinant human tTG in serum</td><td>to gliadin in human serum</td></tr><tr><td>Indications for Use</td><td>in human serum Aid in the diagnosis of IgA/IgG celiac disease and dermatitis herpetiformis</td><td>Anti-hu tTG IgA: Aid in the diagnosis of celiac disease and dermatitis herpetiformis Anti-hu tTG IgG: Aid in the diagnosis of celiac disease in patients</td><td>Aid in the diagnosis of celiac disease and dermatitis herpetiformis</td></tr><tr><td>Positive and Negative Control</td><td>To be diluted 1:101 with 1X Wash</td><td>with IgA deficiency Pre-diluted human serum. Ready to</td><td>Pre-diluted human serum. Ready to</td></tr><tr><td>Calibrator</td><td>buffer One calibrator</td><td>use. Set of four calibrators</td><td>use. Set of four calibrators</td></tr><tr><td>Conjugate</td><td>Goat anti-human IgA (α chain specific) and IgG (Fcγ specific) horseradish</td><td>Anti-human IgA/IgG alkaline phosphatase conjugate</td><td>Anti-human IgA or IgG alkaline phosphatase conjugate</td></tr><tr><td>Serum Dilution Assay wash step</td><td>peroxidase 1:101 3X wash twice</td><td>1:51 4X wash twice</td><td>1:51 4X wash twice</td></tr><tr><td>Incubation</td><td>30-30-15 (IgA and IgG)</td><td>60-30-30 (IgA) 30-30-30 (IgG)</td><td>30-30-15 (IgA and IgG)</td></tr><tr><td>Reading after Stop solution</td><td>Within 30 min</td><td>Within 1 hour</td><td>Within 1 hour</td></tr><tr><td>Result Interpretation</td><td>≥ 20 U/mL: Normal 21-25: Equivocal &gt;25: Abnormal</td><td>&lt; 20 EU/mL: Neg 20-25: Borderline &gt;25: Positive</td><td>Children: AGA-IgA: &lt;23 EU/mL: Neg &gt;23: Positive AGA-IgG: &lt;28 EU/mL: Neg &gt;28: Positive</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="2" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Adults:AGA-IgA andAGA-IgG:&lt;20 EU/mL: Neg&gt;20: Positive</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

Not applicable

# L. Test Principle:

The TheraTest EL-tTG™ IgA/IgG or The TheraTest EL-Gliadin™ $\mathrm { I g A / I g G }$ Test System is a solid phase enzyme immonoassay in a 96-well plate format for the measurement of IgA and IgG antibodies against tissue transglutaminase or gliadin. Wells are coated with human recombinant tissue transglutaminase or purified gliadin, and incubated with Specimens, Calibrators, Positive and Negative Controls. During the incubation, anti-tTG or anti-gliadin antibodies present in the test sample are bound to the solid phase antigen. The wells are subsequently washed, and isotypespecific horseradish-peroxidase labeled anti-human immunoglobulin antibody (enzyme conjugate) is added. After incubating the wells with the enzyme conjugate, unbound labeled antibody is removed by washing. A chromogenic substrate solution is then added to the wells, and the presence of antibodies to tissue transglutaminase is detected by a color change produced by the conversion of the substrate by the enzyme. The reaction is stopped, and the intensity of the color, which is proportional to the amount of the bound antibody, is read by an ELISA reader. The absorbance value in the blank well (incubated with Specimen Diluent) is subtracted from the values obtained with Specimens, Calibrators and Controls.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Intra-assay studies on anti-tTG IgA/IgG and anti-Gliadin IgA/IgG: Three specimens (high, moderate and near cut-off) were assayed for a total of 20 times and two runs per day. The mean units for anti-tTG IgA ranged from 26 to 187 units and the mean units for anti-tTG IgG ranged from 29 to 83 units. The percent CV for anti-tTG IgA ranged from $2 . 8 \% - 1 0 . 9 \%$ and for anti-tTG IgG, $2 . 9 \% - 5 . 3 \%$ . The mean units for anti-Gliadin IgA ranged from 29 to 154 units and the mean units for anti-Gliadin IgG ranged from 23 to 88 units. The percent CV for anti-Gliadin IgA ranged from $4 . 0 \% - 7 . 6 \%$ and for anti-Gliadin IgG $2 . 4 \% - 1 0 . 8 \%$ .

Inter-assay studies on anti-tTG $\mathrm { I g A / I g G }$ and anti-Gliadin $\mathrm { I g A / I g G }$ :

Three specimens (high, moderate and near cut-off) were assayed for a total of 20 different times in one or two runs. The mean units for anti-tTG IgA ranged from 30 to 193 units and for anti-tTG IgG ranged from 27 to 83 units. The percent CV for anti-tTG IgA ranged from $3 . 9 \% - 1 0 . 1 \%$ and $7 . 8 \% - 1 0 . 7 \%$ for anti-tTG IgG. The mean units for anti-Gliadin IgA ranged from 34 to 134 units and the mean units for anti-Gliadin IgG ranged from 29 to 65 units. The percent CV for anti-Gliadin IgA ranged from $8 . 4 \% - 1 0 . 1 \%$ and $9 . 0 \%$ – $1 0 . 2 \%$ for anti-Gliadin IgG.

$b$ . Linearity/assay reportable range: Not applicable.

There are no reference standards for tTG and gliadin. The results are reported in arbitrary units.

d. Detection limit:

Not applicable.

e. Analytical specificity:

Interference by endogenous substances: No data provided. The package insert states that grossly hemolyzed, lipemic, icteric or microbially contaminated serum should not be used in this assay.

Crossreactivity with other autoantibodies: Testing was performed with 56 sera consisting of 40 inflammatory bowel disease (IBD) and 16 thyroid disease.

The positive samples were: one IBD with anti-tTG IgA, one IBD with antitTG IgG, two IBD with anti-gliadin IgA, one IBD with anti-gliadin IgG and one thyroid disease with anti-gliadin IgG.

$f .$ Assay cut-off:

The cut-off value of ${ > } 2 5 \ \mathrm { U / m L }$ was established based on testing 100 blood bank donors. There were 51 females and 49 males with a median age of 29 years and a range from 16 to 70 years. The race distribution was $14 \%$ Hispanic, $8 \%$ Black, $4 \%$ Asian, and $74 \%$ other. The $9 8 ^ { \mathrm { t h } }$ percentile was used to establish the upper limit of normal for IgA and IgG Anti-tTG and the $9 7 . 5 ^ { \mathrm { t h } }$ and $9 4 ^ { \mathrm { t h } }$ percentile were used to establish for IgA and IgG Anti-gliadin respectively.

2. Comparison studies:

a. Method comparison with predicate device: Testing was performed on 106 samples (42 from IgA sufficient CD patients, 14 from IgA deficient patients and 50 healthy donors). The comparative study on anti-tTG IgA had a $100 \%$ Positive Percent Agreement (40/40) ( $9 5 \%$ CI: $91 \% 1 0 - 1 0 0 \% )$ ); $9 7 \%$ Negative Percent Agreement (64/66) ( $9 5 \%$ CI: $8 9 \% { - } 1 0 0 \%$ ; and $9 8 \%$ Overall Agreement (104/106) $9 5 \%$ CI: $9 3 \% - 1 0 0 \%$ ). Refer to table below:

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>ImmuLisaTM Anti-hu tTG IgA</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>EL-tTGTMIgA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>42</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>64</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>106</td></tr></table>

The comparative study on anti-tTG IgG had a Positive Percent Agreement of $84 \%$ (27/32) $9 5 \%$ CI: $6 7 \% - 9 5 \% )$ ); $9 5 \%$ Negative Percent Agreement (62/65) ( $9 5 \%$ CI: $8 7 \% - 9 9 \%$ ); and $92 \%$ Overall agreement (89/97) $9 5 \%$ CI: $84 \%$ -

$9 6 \%$ ). Refer to table below:

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=4>ImmuLisaTM Anti-hu tTG IgG</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Equivocal*</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=4 colspan=1>EL-tTGTMIgG</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>(4)</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Equivocal*</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>(1)</td><td rowspan=1 colspan=1>(3)</td><td rowspan=1 colspan=1>(4)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>(1)</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>67</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>(6)</td><td rowspan=1 colspan=1>65</td><td rowspan=1 colspan=1>97</td></tr></table>

\*Equivocals were excluded from the calculation.

The comparative study on anti-Gliadin IgA had a $9 5 \%$ Positive Percent Agreement (21/22) $9 5 \%$ CI: $7 7 \% - 1 0 0 \%$ ); $9 6 \%$ Negative Percent Agreement (78/81) $9 5 \%$ CI: $90 \% - 9 9 \%$ ); and $9 6 \%$ Overall Agreement (99/103) ( $9 5 \%$ CI: $90 \% - 9 9 \%$ ). Refer to table below:

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>ImmuLisaTM Anti-Gliadin IgA</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=4 colspan=1>EL-GliaTMIgA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Equivocal*</td><td rowspan=1 colspan=1>(2)</td><td rowspan=1 colspan=1>(1)</td><td rowspan=1 colspan=1>(3)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>79</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>81</td><td rowspan=1 colspan=1>103</td></tr></table>

\*Equivocals were excluded from the calculation.

The comparative study on anti-Gliadin $\mathrm { I g G }$ had a $8 1 \%$ Positive Percent Agreement (29/36) ( $9 5 \%$ CI: $6 4 \% - 9 2 \%$ ); $92 \%$ Negative Percent Agreement (58/63) ( $9 5 \%$ CI: $8 2 \% - 9 7 \%$ ); and $8 8 \%$ Overall Agreement (87/99) $9 5 \%$ CI: $80 \% 9 4 \%$ ). Refer to table below:

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>ImmuLisaTM Anti-Gliadin IgA</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=4 colspan=1>EL-GliaTMIgG</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>34</td></tr><tr><td rowspan=1 colspan=1>Equivocal*</td><td rowspan=1 colspan=1>(6)</td><td rowspan=1 colspan=1>(1)</td><td rowspan=1 colspan=1>(7)</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>65</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>36</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>99</td></tr></table>

\*Equivocals were excluded from the calculation.

b. Matrix comparison: Both assays use serum as the sample matrix.

3. Clinical studies:

a. Clinical Sensitivity and specificity Samples used in the studies for determination of clinical sensitivity and specificity consisted of 44 samples from Celiac disease patients, 40 IBD, 16 thyroid disease patients and 100 blood bank donors. Samples from IBD, thyroid disease and the blood donors were combined as the control group. For anti-tTG IgA, clinical sensitivity was $9 5 \%$ (42/44) and clinical specificity was $9 8 \%$ (153/156) (refer to table below):

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Celiac disease*(n=44)</td><td rowspan=1 colspan=1>Control group(n=156)</td><td rowspan=1 colspan=1>Total(n=200)</td></tr><tr><td rowspan=4 colspan=1>EL-tTGTMIgA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>42</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2**</td><td rowspan=1 colspan=1>153</td><td rowspan=1 colspan=1>155</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>200</td></tr></table>

\* The group includes patients on gluten-containing and gluten-restricted diet, as well. \*\* IgA deficient patients

For anti-tTG $\mathrm { I g G }$ , clinical sensitivity was $48 \%$ (21/44) and clinical specificity was $9 7 \%$ (152/156) (refer to table below):

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Celiac disease*(n=44)</td><td rowspan=1 colspan=1>Control group(n=156)</td><td rowspan=1 colspan=1>Total(n=200)</td></tr><tr><td rowspan=4 colspan=1>EL-tTGTMIgG</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>5</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>152</td><td rowspan=1 colspan=1>171</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>200</td></tr></table>

\* The group includes patients on gluten-containing and gluten-restricted diet, as well.

For anti-Gliadin IgA, clinical sensitivity was $5 5 \%$ (24/44) and clinical specificity was $9 5 \%$ (148/156) (see table below):

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Celiac disease*(n=44)</td><td rowspan=1 colspan=1>Control group(n=156)</td><td rowspan=1 colspan=1>Total(n=200)</td></tr><tr><td rowspan=4 colspan=1>EL-GliaTMIgA</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>28</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>7</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>17**</td><td rowspan=1 colspan=1>148</td><td rowspan=1 colspan=1>165</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>200</td></tr></table>

\* The group includes patients on gluten-containing and gluten-restricted diet, as well. \*\*Two patients in this group are IgA deficient

For anti-Gliadin IgG, clinical sensitivity was $5 5 \%$ (24/44) and clinical specificity was $94 \%$ (146/156) (see table below):

<table><tr><td rowspan=2 colspan=2></td><td rowspan=1 colspan=3>Diagnosis</td></tr><tr><td rowspan=1 colspan=1>Celiac disease*(n=44)</td><td rowspan=1 colspan=1>Control group(n=156)</td><td rowspan=1 colspan=1>Total(n=200)</td></tr><tr><td rowspan=4 colspan=1>EL-GliaTMIgG</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>30</td></tr><tr><td rowspan=1 colspan=1>Equivocal</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>9</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>146</td><td rowspan=1 colspan=1>161</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>156</td><td rowspan=1 colspan=1>200</td></tr></table>

\* The group includes patients on gluten-containing and gluten-restricted diet, as well b. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Same as assay cut-off.   
5. Expected values/Reference range: Expected values in the normal population should be negative.

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision.